CCB02 NEW
| Price | $70 | $173 | $273 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-05-30 |
Product Details
| Product Name: CCB02 | CAS No.: 2100864-57-9 |
| Purity: 99.98% | Supply Ability: 10g |
| Release date: 2026/05/30 |
Product Introduction
Bioactivity
| Name | CCB02 |
| Description | CCB02 is a selective CPAP-tubulin interaction inhibitor (IC50: 689 nM) with anti-tumor activity, showing no inhibition on cell cycle- and centrosome-related kinases, nor affecting the phosphorylation status of Aurora-A, CDK2, Plk1, Plk2, and CHK1. |
| In vitro | CCB02 perturbs CPAP PN2-3-tubulin interaction with an IC50 of 0.441 μM in a PN2-3 CPAP-GST pull-down assay. In concentrations ranging from 0.1 to 15 μM over 72 hours, CCB02 inhibits the proliferation of cancer cells with extra centrosomes (IC50s: 0.86-2.9 μM). Additionally, CCB02 activates the spindle assembly checkpoint, induces PCM proteins recruitment to centrosomes, and enhances the microtubule nucleation activities of centrosomes[1]. |
| In vivo | CCB02 (30 mg/kg, p.o. daily for 24 days) exhibits a potent anti-tumor effect in nude mice with subcutaneous human lung (H1975 T790M cells) tumor xenografts, suppresses MDA-MB-231 cell migration, and induces multipolar mitosis in mouse xenografts[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+90% Corn Oil : 2 mg/mL (8.5 mM), Sonication is recommended. DMSO : 22.5 mg/mL (95.65 mM), Sonication is recommended. |
| Keywords | MicrotubuleAssociated | Microtubule Associated | CPAP-tubulin | CCB-02 | CCB02 | CCB 02 |
| Inhibitors Related | Flubendazole | N-Phenylbenzylamine | Mebendazole | 4-Isopropoxybenzoic acid | Pregnenolone acetate | Oxfendazole | α-Cyclodextrin | Methylene Blue trihydrate | Paclitaxel | 4'-Demethylepipodophyllotoxin | Albendazole | Colchicine |
| Related Compound Libraries | Bioactive Compound Library | Protease Inhibitor Library | Inhibitor Library | PPI Inhibitor Library | Bioactive Compounds Library Max | Cytoskeletal Signaling Pathway Compound Library | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library | High-Efficiency Gene Editing Small Molecule Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $70.00 |
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-05-30 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY